scholarly journals Acute hormonal response to sublingual androstenediol intake in young men

2002 ◽  
Vol 92 (1) ◽  
pp. 142-146 ◽  
Author(s):  
Gregory A. Brown ◽  
Emily R. Martini ◽  
B. Scott Roberts ◽  
Matthew D. Vukovich ◽  
Douglas S. King
Keyword(s):  
Peak Concentration ◽  
Young Men ◽  
Serum Testosterone ◽  
Free Testosterone ◽  
Total Testosterone ◽  
Serum Estradiol ◽  
Hormonal Response ◽  
Double Blind ◽  
First Pass ◽  
Serum Hormone

The effectiveness of orally ingested androstenediol in raising serum testosterone concentrations may be limited because of hepatic breakdown of the ingested androgens. Because androstenediol administered sublingually with cyclodextrin bypasses first-pass hepatic catabolism, we evaluated the acute hormonal response to sublingual cyclodextrin androstenediol supplement in young men. Eight men (22.9 ± 1.2 yr) experienced in strength training consumed either 20 mg androstenediol in a sublingual cyclodextrin tablet (Sl Diol) or placebo (Pl) separated by at least 1 wk in a randomized, double-blind, crossover manner. Blood samples were collected before supplementation and at 30-min intervals for 3 h after supplementation. Serum hormone concentrations did not change with Pl. Serum androstenedione concentrations were increased ( P < 0.05) above baseline (11.2 ± 1.1 nmol/l) with Sl Diol from 60 to 180 min after intake and reached a peak concentration of 25.2 ± 2.9 nmol/l at 120 min. Serum free testosterone concentrations were increased from 86.2 ± 9.1 pmol/l with Sl Diol from 30 to 180 min and reached a peak concentration of 175.4 ± 12.2 pmol/l at 60 min. Serum total testosterone concentrations increased above basal (25.6 ± 2.3 nmol/l) from 30 to 180 min with Sl Diol and reached a peak concentration of 47.9 + 2.9 nmol/l at 60 min. Serum estradiol concentrations were elevated ( P < 0.05) above baseline (0.08 ± 0.01 nmol/l) from 30 to 180 min with Sl Diol and reached 0.14 ± 0.02 nmol/l at 180 min. These data indicate that sublingual cyclodextrin androstenediol intake increases serum androstenedione, free testosterone, total testosterone, and estradiol concentrations.

Effects of Anabolic Precursors on Serum Testosterone Concentrations and Adaptations to Resistance Training in Young Men

2000 ◽  
Vol 10 (3) ◽  
pp. 340-359 ◽  
Author(s):  
Gregory A. Brown ◽  
Matthew D. Vukovich ◽  
Tracy A. Reifenrath ◽  
Nathaniel L. Uhl ◽  
Kerry A. Parsons ◽  
...  
Keyword(s):  
Resistance Training ◽  
Young Men ◽  
Serum Testosterone ◽  
Acute Effect ◽  
Total Testosterone ◽  
Tribulus Terrestris ◽  
Serum Estradiol ◽  
Herbal Extracts ◽  
Treatment Groups ◽  
Daily Dose

The effects of androgen precursors, combined with herbal extracts designed to enhance testosterone formation and reduce conversion of androgens to estrogens was studied in young men. Subjects performed 3 days of resistance training per week for 8 weeks. Each day during Weeks 1,2,4,5,7, and 8, subjects consumed either placebo (PL; n = 10) or a supplement (ANDRO-6; n = 10), which contained daily doses of 300 mg androstenedione, 150 mg DHEA, 750 mg Tribulus terrestris, 625 mg Chrysin, 300 mg Indole-3-carbinol, and 540 mg Saw palmetto. Serum androstenedione concentrations were higher in ANDRO-6 after 2,5, and 8 weeks (p < .05), while serum concentrations of free and total testosterone were unchanged in both groups. Serum estradiol was elevated at Weeks 2, 5, and 8 in ANDRO-6 (p < .05), and serum estrone was elevated at Weeks 5 and 8 (p < .05). Muscle strength increased (p < .05) similarly from Weeks 0 to 4, and again from Weeks 4 to 8 in both treatment groups. The acute effect of one third of the daily dose, of ANDRO-6 and PL was studied in 10 men (23±4years). Serum androstenedione concentrations were elevated (p < .05) in ANDRO-6 from 150 to 360 min after ingestion, while serum free or total testosterone concentrations were unchanged. These data provide evidence that the addition of these herbal extracts to androstenedione does not result in increased serum testosterone concentrations, reduce the estrogenic effect of androstenedione, and does not augment the adaptations to resistance training.

Perfluoroalkyl and Polyfluoroalkyl substance exposure and association with sex hormone concentrations: Results from the NHANES 2015 -2016

2021 ◽  
Author(s):  
Xin Xie ◽  
Xueqiong Weng ◽  
Shan Liu ◽  
Jingmin Chen ◽  
Xinrong Guo ◽  
...  
Keyword(s):  
Sex Hormones ◽  
Serum Testosterone ◽  
Free Testosterone ◽  
Epidemiological Studies ◽  
Sex Hormone ◽  
Total Testosterone ◽  
Negatively Associated ◽  
Serum Hormone ◽  
Pfos Exposure ◽  
Estradiol Levels

Abstract Background: There is increasing global concern regarding the health impacts of perfluoroalkyl and polyfluoroalkyl substances (PFAS), which are emerging environmental endocrine disruptors. Results from previous epidemiological studies on the associations between PFAS exposure and sex hormone levels are inconsistent.Objective: We examined the associations between serum PFAS compounds (PFDeA, PFHxS, PFNA, PFOA, PFOS) and sex hormones, including total testosterone (TT), free testosterone (FT), estrogen (E), and serum hormone binding globulin (SHBG).Results: After adjusting for potential confounders, PFDeA, PFOS, and PFHxS exposures were significantly associated with increased serum testosterone concentrations in males. PFDeA, PFOA, and PFOS exposures were positively correlated with FT levels in 20-49 years old women while PFOS exposure was negatively associated with TT levels in 12-19 years old girls. PFAS exposure was negatively associated with estradiol levels including: PFDeA in all females, PFHxS, PFNA, PFOS, and PFOA in 12-19 years old girls, PFNA in women above 50 years old, and PFOA in 12-19 years old boys while PFDeA and PFOS exposures were positively associated with estradiol levels in these boys. n-PFOS exposure was positively associated with SHBG levels in men older than 20 and in all females.Conclusions: Using a large cohort of males and females aged from 12-80, we found that PFAS exposure appears to disrupt sex hormones in a gender-, age-, and compound-specific manner. Future work is warranted to clarify the causality and mechanisms involved.

scholarly journals Perfluoroalkyl and polyfluoroalkyl substance exposure and association with sex hormone concentrations: results from the NHANES 2015–2016

2021 ◽  
Vol 33 (1) ◽  
Author(s):  
Xin Xie ◽  
Xueqiong Weng ◽  
Shan Liu ◽  
Jingmin Chen ◽  
Xinrong Guo ◽  
...  
Keyword(s):  
Sex Hormones ◽  
Serum Testosterone ◽  
Free Testosterone ◽  
Epidemiological Studies ◽  
Sex Hormone ◽  
Total Testosterone ◽  
Negatively Associated ◽  
Serum Hormone ◽  
Pfos Exposure ◽  
Estradiol Levels

Abstract Background There is increasing global concern regarding the health impacts of perfluoroalkyl and polyfluoroalkyl substances (PFAS), which are emerging environmental endocrine disruptors. Results from previous epidemiological studies on the associations between PFAS exposure and sex hormone levels are inconsistent. Objective We examined the associations between serum PFAS compounds (PFDeA, PFHxS, PFNA, PFOA, PFOS) and sex hormones, including total testosterone (TT), free testosterone (FT), estradiol (E), and serum hormone binding globulin (SHBG). Results After adjusting for potential confounders, PFDeA, PFOS, and PFHxS exposures were significantly associated with increased serum testosterone concentrations in males. PFDeA, PFOA, and PFOS exposures were positively correlated with FT levels in 20–49-year-old women, while PFOS exposure was negatively associated with TT levels in 12–19-year-old girls. PFAS exposure was negatively associated with estradiol levels including: PFDeA in all females, PFHxS, PFNA, PFOS, and PFOA in 12–19-year-old girls, PFNA in women above 50 years, and PFOA in 12–19-year-old boys, while PFDeA and PFOS exposures were positively associated with estradiol levels in these boys. n-PFOS exposure was positively associated with SHBG levels in men older than 20 and in all females. Conclusions Using a large cohort of males and females aged from 12 to 80, we found that PFAS exposure appears to disrupt sex hormones in a sex-, age-, and compound-specific manner. Future work is warranted to clarify the causality and mechanisms involved.

scholarly journals Effect of oral DHEA on serum testosterone and adaptations to resistance training in young men

1999 ◽  
Vol 87 (6) ◽  
pp. 2274-2283 ◽  
Author(s):  
Gregory A. Brown ◽  
Matthew D. Vukovich ◽  
Rick L. Sharp ◽  
Tracy A. Reifenrath ◽  
Kerry A. Parsons ◽  
...  
Keyword(s):  
Resistance Training ◽  
Young Men ◽  
Serum Testosterone ◽  
Treated Group ◽  
Whole Body ◽  
Total Testosterone ◽  
Resistance Training Program ◽  
Body Resistance ◽  
Liver Transaminases ◽  
And Training

This study examined the effects of acute dehydroepiandrosterone (DHEA) ingestion on serum steroid hormones and the effect of chronic DHEA intake on the adaptations to resistance training. In 10 young men (23 ± 4 yr old), ingestion of 50 mg of DHEA increased serum androstenedione concentrations 150% within 60 min ( P < 0.05) but did not affect serum testosterone and estrogen concentrations. An additional 19 men (23 ± 1 yr old) participated in an 8-wk whole body resistance-training program and ingested DHEA (150 mg/day, n = 9) or placebo ( n = 10) during weeks 1, 2, 4, 5, 7, and 8. Serum androstenedione concentrations were significantly ( P < 0.05) increased in the DHEA-treated group after 2 and 5 wk. Serum concentrations of free and total testosterone, estrone, estradiol, estriol, lipids, and liver transaminases were unaffected by supplementation and training, while strength and lean body mass increased significantly and similarly ( P < 0.05) in the men treated with placebo and DHEA. These results suggest that DHEA ingestion does not enhance serum testosterone concentrations or adaptations associated with resistance training in young men.

Decreased serum testosterone and free triiodothyronine levels in healthy middle-aged men indicate an age effect at the pituitary level

1995 ◽  
Vol 132 (6) ◽  
pp. 663-667 ◽  
Author(s):  
Eva Marie T Erfurth ◽  
Lars E Hagmar
Keyword(s):  
Luteinizing Hormone ◽  
Young Men ◽  
Serum Testosterone ◽  
Free Testosterone ◽  
Age Effect ◽  
Hormone Response ◽  
Middle Aged ◽  
Free Triiodothyronine ◽  
Thyrotrophin Releasing Hormone ◽  
Releasing Hormone

Erfurth EMT, Hagmar LE. Decreased serum testosterone and free triidothyronine levels in healthy middle-aged men indicate an age effect at the pituitary level. Eur J Endocrinol 1995;132:663–7. ISSN 0804–4643 In an attempt to study further the age-specific influence on the hypothalamo-pituitary–gonadal axis as well as the hypothalamo–pituitary–thyroid axis, we have now investigated young and middle-aged men, considering possible confounding factors. Both serum total testosterone, free testosterone and the total ratio of testosterone to sex-hormone binding globulin were significantly lower among middle-aged men as compared with young men (p = 0.02, p = 0.002 and p = 0.0003, respectively). In accordance with these findings there was also a decrease in the luteinizing hormone response to gonadotrophin-releasing hormone in the middle-aged men (p= 0.02). Free testosterone was correlated significantly with the luteinizing hormone response (r = 0.32, p = 0.02). Serum free triiodothyronine was significantly higher among young men as compared with middle-aged men (p = 0.002) and the thyrotrophin-releasing hormone-stimulated thyrotrophin response was also higher in the young group compared with the middle-aged group. The present results may indicate that the age effect on serum levels of testosterone and free triidothyronine is mediated at the pituitary level. Eva Marie Erfurth, Dept. of Internal Medicine, University of Lund, S-221 85 Lund, Sweden

scholarly journals Effect of Eurycoma longifolia standardised aqueous root extract– Physta® on testosterone levels and quality of life in ageing male subjects: a randomised, double-blind, placebo-controlled multicentre study

2021 ◽  
Author(s):  
Sasikala M. Chinnappan ◽  
Annie George ◽  
Pragya Pandey ◽  
Govinda Narke ◽  
Yogendra Kumar Choudhary
Keyword(s):  
Quality Of Life ◽  
Free Testosterone ◽  
Total Testosterone ◽  
Double Blind ◽  
Testosterone Levels ◽  
Eurycoma Longifolia ◽  
Ageing Male ◽  
Secondary Endpoints ◽  
Male Subjects

Background: Low testosterone levels cause physiological changes that compromise the quality of life in ageing men. A standardised water extract from the root of Eurycoma longifolia (EL), known as Physta®, is known to increase testosterone levels. Objective: To evaluate the safety and efficacy of Physta® in improving the testosterone levels and quality of life in ageing male subjects. Design: This randomised, double-blind, placebo-controlled study enrolled 105 male subjects aged 50–70 years with a testosterone level <300 ng/dL, BMI ≥ 18 and ≤30.0 kg/m2. The subjects were given either Physta® 100 mg, 200 mg or placebo daily for 12 weeks. The primary endpoints were changes in serum total and free testosterone levels. The secondary endpoints included changes in the level of sex hormone-binding globulin (SHBG), dihydroepiandrosterone (DHEA), glycated haemoglobin (HbA1c), insulin-like growth factor-1 (IGF-1), thyroid function tests (T3, T4, TSH and Free T3) and cortisol. Changes in Ageing Male Symptoms (AMS) score, Fatigue Severity Scale (FSS) score and muscle strength are other secondary endpoints. The safety of the intervention products was measured by complete blood count, lipid profile, liver and renal function tests. Results: There was a significant increase in the total testosterone levels at week 12 (P < 0.05) in the Physta® 100 mg group and at weeks 4 (P < 0.05), 8 (P < 0.01) and 12 (P < 0.001) in the Physta® 200 mg group compared to placebo. No significant between-group differences in free testosterone levels were observed but a significant within-group increase occurred at weeks 4 (P < 0.01), 8 (P < 0.001) and 12 (P < 0.001) in the Physta®100 mg group and at weeks 2 (P < 0.01), 4 (P < 0.01), 8 (P < 0.001) and 12 (P < 0.001) in the Physta® 200 mg group. The AMS and FSS showed significant reduction (P < 0.001) in total scores at all time-points within- and between-group in both Physta® groups. DHEA levels significantly increased (P < 0.05) within-group in both Physta® groups from week 2 onwards. Cortisol levels significantly (P < 0.01) decreased in the Physta® 200 mg group, while muscle strength significantly (P < 0.001) increased in both Physta® groups at week 12 in the within-group comparison. There were no significant changes in SHBG. No safety related clinically relevant changes were observed. Conclusion: Supplementation of Physta® at 200 mg was able to increase the serum total testosterone, reduce fatigue and improve the quality of life in ageing men within 2 weeks’ time. Trial registration: This clinical study has been registered in ctri.nic.in (CTRI/2019/03/017959).

scholarly journals Furosap, a novel Fenugreek seed extract improves lean body mass and serum testosterone in a randomized, placebo-controlled, double-blind clinical investigation

2018 ◽  
Vol 8 (11) ◽  
pp. 519 ◽  
Author(s):  
Rui Guo ◽  
Qiurong Wang ◽  
Rama P. Nair ◽  
Scarlet L. Barnes ◽  
Derek T. Smith ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Lean Body Mass ◽  
Body Mass ◽  
Testosterone Level ◽  
Serum Testosterone ◽  
Seed Extract ◽  
Fat Free Mass ◽  
Total Testosterone ◽  
Double Blind ◽  
Fenugreek Seed

Background: The Indian spice fenugreek (Trigonella foenum-graecum) has been credited with numerous health benefits in cardiovascular disorders, metabolic syndrome, inflammatory conditions, glucose-insulin regulation, and sports performance. Previous studies from our laboratories demonstrated that fenugreek seed extract improved glucose tolerance, insulin sensitivity, augmented serum testosterone level and improved cardiovascular functions. Our investigation examined the efficacy of Furosap, a novel fenugreek seed extract enriched in 20% protodioscin, on exercise performance. Methods: This randomized, double-blind, placebo-controlled, clinical study was conducted in forty healthy male athletes (n = 40) over a period of 12 consecutive weeks. Subjects were given either placebo or Furosap capsules (250 mg/day b.d.) and serum samples were used to assess serum total testosterone level and C-reactive proteins (CRP) at baseline and at the end of 12-weeks of treatment. Body fat mass, lean mass, fat mass, fat-free mass, grip strength, upper and lower body strength, maximal graded exercise stress using a digital hand dynamometer, dual-energy X-ray absorptiometry (DEXA), force plate, and treadmill with open-circuit spirometry were assessed at the baseline and at the end of 12-weeks of treatment.Results: Furosap supplementation significantly increased mean lean body mass and fat-free mass compared to subjects receiving placebo. Additionally, Furosap-treated subjects elevated serum testosterone levels. Furosap supplemented subjects also exhibited a tendency towards lowering blood pressure during exhaustion. No adverse reports were reported.Conclusions: Given improvement of lean body mass and serum total testosterone following intervention with Furosap, Furosap likely has benefits for exercise endurance and sports medicine. Keywords: Fenugreek seed extract; safety; body mass; fat-free mass; blood pressure; muscle strength.

Vigorous Physical Activity is Associated with Regular Aerobic Exercise-Induced Increased Serum Testosterone Levels in Overweight/Obese Men

2017 ◽  
Vol 50 (01) ◽  
pp. 73-79 ◽  
Author(s):  
Hiroshi Kumagai ◽  
Toru Yoshikawa ◽  
Asako Zempo-Miyaki ◽  
Kanae Myoenzono ◽  
Takehiko Tsujimoto ◽  
...  
Keyword(s):  
Physical Activity ◽  
Aerobic Exercise ◽  
Exercise Intervention ◽  
Vigorous Physical Activity ◽  
Serum Testosterone ◽  
Free Testosterone ◽  
Normal Weight ◽  
Total Testosterone ◽  
Testosterone Levels ◽  
Bioavailable Testosterone

AbstractTestosterone is a male sex hormone and low circulating testosterone levels are associated with various health disorders in men. Obesity results in reduced circulating testosterone levels in men. Previously, we demonstrated that lifestyle modifications (combination of aerobic exercise and dietary modification) increase circulating testosterone levels in overweight/obese men. However, the effect of regular aerobic exercise on serum testosterone levels remains unclear. The purpose of this study was to investigate the effect of a 12-week aerobic exercise intervention on circulating testosterone levels in normal-weight and overweight/obese men. Sixteen normal-weight men and twenty-eight overweight/obese men completed a 12-week aerobic exercise intervention. Before and after the intervention, we measured serum total testosterone, free testosterone, and bioavailable testosterone levels, and categorized the physical activity levels (light, moderate, or vigorous) in all participants. At baseline, serum total testosterone, free testosterone, and bioavailable testosterone levels were significantly lower in overweight/obese men than in normal-weight men (all p<0.01). After the 12-week aerobic exercise intervention, serum total testosterone, free testosterone, and bioavailable testosterone levels significantly increased in overweight/obese men (p<0.01). In addition, stepwise multivariable linear regression analysis revealed the increase in vigorous physical activity was independently associated with increased serum total testosterone levels (β=0.47, p=0.011). We demonstrated that a 12-week aerobic exercise intervention increased serum total testosterone, free testosterone, and bioavailable testosterone levels in overweight/obese men. We suggest that an increase in vigorous physical activity increased circulating testosterone levels in overweight/obese men.

scholarly journals Letrozole once a week normalizes serum testosterone in obesity-related male hypogonadism

2008 ◽  
Vol 158 (5) ◽  
pp. 741-747 ◽  
Author(s):  
Sandra Loves ◽  
Janneke Ruinemans-Koerts ◽  
Hans de Boer
Keyword(s):  
Hypogonadotropic Hypogonadism ◽  
Serum Testosterone ◽  
Free Testosterone ◽  
Total Testosterone ◽  
Male Hypogonadism ◽  
Serum Lh ◽  
Long Term Effect ◽  
Starting Dose ◽  
Severely Obese ◽  
Lh Secretion

ObjectiveIsolated hypogonadotropic hypogonadism (IHH) is frequently observed in severely obese men, probably as a result of increased estradiol (E2) production and E2-mediated negative feedback on pituitary LH secretion. Aromatase inhibitors can reverse this process. This study evaluates whether letrozole once a week can normalize serum testosterone in severely obese men and maintain its long term effect.DesignOpen, uncontrolled 6-month pilot study in 12 severely obese men (body mass index>35.0 kg/m2) with obesity-related IHH and free testosterone levels <225 pmol/l, treated with 2.5 mg letrozole once a week for 6 months.ResultsSix weeks of treatment reduced total E2 from 123±11 to 58±7 pmol/l (P<0.001, mean±s.e.m.), and increased serum LH from 4.4±0.6 to 11.1±1.5 U/l (P<0.001). Total testosterone rose from 5.9±0.5 to 19.6±1.4 nmol/l (P<0.001), and free testosterone from 163±13 to 604±50 pmol/l (P<0.001). Total testosterone rose to within the normal range in all subjects, whereas free testosterone rose to supraphysiological levels in 7 out of 12 men. The testosterone and E2 levels were stable throughout the week and during the 6-month treatment period.ConclusionLetrozole 2.5 mg once a week produced a sustained normalization of serum total testosterone in obese men with IHH. However, free testosterone frequently rose to supraphysiological levels. Therefore, a starting dose <2.5 mg once a week is recommended.

scholarly journals Differences in the Apparent Metabolic Clearance Rate of Testosterone in Young and Older Men with Gonadotropin Suppression Receiving Graded Doses of Testosterone

2006 ◽  
Vol 91 (11) ◽  
pp. 4669-4675 ◽  
Author(s):  
Andrea D. Coviello ◽  
Kishore Lakshman ◽  
Norman A. Mazer ◽  
Shalender Bhasin
Keyword(s):  
Lean Body Mass ◽  
Body Mass ◽  
Young Men ◽  
Serum Testosterone ◽  
Older Men ◽  
Total Testosterone ◽  
Metabolic Clearance ◽  
Clearance Rates ◽  
Testosterone Levels ◽  
Age Related

Abstract Background: Recently we found that testosterone levels are higher in older men than young men receiving exogenous testosterone. We hypothesized that older men have lower apparent testosterone metabolic clearance rates (aMCR-T) that contribute to higher testosterone levels. Objective: The objective of the study was to compare aMCR-T in older and young men and identify predictors of aMCR-T. Methods: Sixty-one younger (19–35 yr) and 60 older (59–75 yr) men were given a monthly GnRH agonist and weekly testosterone enanthate (TE) (25, 50, 125, 300, or 600 mg) for 5 months. Estimated aMCR-T was calculated from the amount of TE delivered weekly and trough serum testosterone concentrations, corrected for real-time absorption kinetics from the im testosterone depot. Results: Older men had lower total (316 ± 13 vs. 585 ± 26 ng/dl, P &lt; 0.00001) and free testosterone (4 ± 0.1 vs. 6 ± 0.3 ng/dl, P &lt; 0.00001) and higher SHBG (52 ± 3 vs. 33 ± 2 nmol/liter, P &lt; 0.00001) than younger men at baseline. Total and free testosterones increased with TE dose and were higher in older men than young men in the 125-, 300-, and 600-mg dose groups. aMCR-T was lower in older men than young men (1390 ± 69 vs. 1821 ± 102 liter/d, P = 0.006). aMCR-T correlated negatively with age (P = 0.0007), SHBG (P = 0.046), and total testosterone during treatment (P = 0.02) and percent body fat at baseline (P = 0.01) and during treatment (P = 0.004). aMCR-T correlated positively with lean body mass at baseline (P = 0.03) and during treatment (P = 0.01). In multiple regression models, significant predictors of aMCR-T included lean body mass (P = 0.008), percent fat mass (P = 0.009), and SHBG (P = 0.001). Conclusions: Higher testosterone levels in older men receiving TE were associated with an age-related decrease in apparent testosterone metabolic clearance rates. Body composition and SHBG were significant predictors of aMCR-T.

Sign in / Sign up

Export Citation Format

Share Document